One of the other PI3K inhibitors that Dr Dihua Yu is alluding to may be the experimental drug SF1126 being considered also at MD Anderson for clinical trial:
NEW DATA PRESENTED AT AACR MEETING FURTHER SUPPORT THE ADVANCE OF SEMAFORE’S TARGETED PI3K INHIBITOR INTO PHASE l TRIALS
--Studies at M.D. Anderson Show First In Vivo FDG-PET Imaging of SF1126 and Demonstrate Mutational Activation of PI3K as a Potential Marker for Selection of Patients—
However in a detailed discussion in the following article of the mode of action of some of the PI3K inhibitors some of their potential serious side effects are considered :
Threaded Mode